Aaron Levine, PhD, MPhil, BS, Georgia Institute of Technology, Atlanta, GA, offers his highlights from the International Society for Cell & Gene Therapy (ISCT) Annual Meeting 2021. He calls attention to a regulatory session focused on therapeutic deception in direct-to-consumer marketing of unproven cell and gene therapies and the value of hearing from the United States Federal Trade Commission (FTC) on how they interact with regulatory bodies. In addition, he highlights a global regulatory workshop focused on the different ways in which health authorities deal with novel cell therapies, as well as the meeting’s coverage of chimeric antigen receptor (CAR) T-cell therapy and the development of personalized therapies for solid tumors. This interview took place during the ISCT Annual Meeting 2021.
Aaron Levine’s work on ethical and policy issues related to cell therapy and cell manufacturing is supported, in part, by the U.S. National Science Foundation under Grant No. EEC-1648035. Any opinions, findings, and conclusions or recommendations expressed in this material are those of the interviewee(s) and do not necessarily reflect the views of the National Science Foundation.